PAVmed Inc.
360 Madison Avenue
25th Floor
New York, NY 10017
United States
917-813-1828
https://www.pavmed.com
版塊: Healthcare
行業: Medical Devices
全職員工: 107
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Lishan Aklog M.D. | Chairman & CEO | 953.2k | 無 | 1966 |
| Mr. Dennis M. McGrath C.P.A. | President & CFO | 673.5k | 無 | 1957 |
| Mr. Shaun M. O'Neill M.B.A. | Executive VP & COO | 498k | 無 | 1983 |
| Mr. Michael Adam Gordon | Executive VP, General Counsel & Secretary | 710.5k | 無 | 1975 |
| Dr. Brian J. deGuzman M.D. | Executive VP, Chief Technology & Compliance Officer | 427.6k | 無 | 1965 |
| Dr. Suman M. Verma M.D., Ph.D. | Senior VP of Molecular Genetics & Chief Scientific Officer | 無 | 無 | 無 |
| Michael Parks | Vice President of Investor Relations | 無 | 無 | 無 |
| Dr. Deepika A. Lakhani Ph.D. | Senior VP, Chief Regulatory & Quality Officer | 無 | 無 | 無 |
| Dr. Victoria T. Lee M.D. | Senior VP & Chief Medical Officer | 無 | 無 | 無 |
描述
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
公司管治
截至 無 止，PAVmed Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
